Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(R)-N-methyl-N‑2‑propynyl‑1‑indanamine is a synthetic small molecule with the chemical formula C13H15N and a molecular weight of approximately 185.26 g/mol[1][5]. It features an indanamine backbone substituted with both methyl and propynyl groups on the nitrogen atom. The compound is structurally related to other indanamines, which are known for their diverse biological activities. While detailed pharmacological data for this specific enantiomer are limited in public sources, similar compounds in this class have been investigated as monoamine oxidase inhibitors due to their structural similarity to known MAO inhibitors[5]. No approved therapeutic indications or marketed products containing this compound were identified.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (R)-N-methyl-N-2-propynyl-1-indanamine.